Partner with Innovators Driving the Next Wave of Inflammasome Therapeutics into the Clinic with Confidence

The 7th Inflammasome Therapeutics Summit brings together 70+ experts from pharma, biotech, and academia who are leading the charge in targeting the inflammasome pathway for next-generation treatments in inflammation, autoimmunity, and neurodegeneration.

With breakthroughs in NLRP3 inhibition, upstream/downstream pathway modulation, and biomarker validation, this is the definitive platform to align your offerings with the most forward-thinking researchers and drug developers in the field.

Networking Image (4)

Why Partner?

With inflammasome-targeting drug development entering a critical translational phase, your tools and services are essential to helping our scientific leaders overcome key bottlenecks.

This is your opportunity to engage directly with industry and academic decision-makers shaping the future of inflammasome therapeutics and showcase your expertise in providing predictive preclinical models, reliable assays, biomarker strategies, and diagnostic tools that support clear clinical endpoints and robust patient outcomes.

Your solutions can play a critical role in ensuring scientific rigor, accelerating IND-enabling studies, and de-risking clinical progression – ultimately laying the foundation for first-in-class and best-in-class inflammasome-targeted therapies.

Our translational and clinical leaders are looking for:

Validated preclinical models reflective of human inflammasome pathology

Fit-for-purpose assays for pharmacodynamic and MoA readouts

Biomarker and diagnostic platforms to enable patient stratification and endpoint clarity

Specialized CRO support for IND-enabling, toxicology, and translational research

18-768x432

Explore the Agenda

Discover the key discussions from the summit, covering breakthroughs in inflammasome biology, emerging therapeutic targets, and the latest clinical and translational insights.

1-768x432

Partner With Us

Showcase your expertise alongside organizations advancing inflammasome-targeted drug development, from biomarker discovery to translational and clinical research.

17-768x432

Join Biopharma Experts

Connect with leading drug developers, immunology researchers, and biotech innovators working to advance the next generation of inflammasome therapeutics.